Stephenson Cancer Center - Cancer Center Support Grant

家长奖摘要

Parent Award ABSTRACT The Stephenson Cancer Center (SCC) at the University of Oklahoma continued to grow and mature during its third year of NCI Cancer Center Support Grant (CCSG) funding. As the state's only NCI-Designated Cancer Center, the SCC has a critical mission of eliminating cancer in Oklahoma and beyond through: 1) providing the highest level of research-driven, patient centered care; 2) translating novel discoveries to the clinic and community settings; 3) engaging the community and addressing cancer problems prevalent in the catchment area; and 4) training the next generation of cancer researchers and health professionals. This mission is especially critical in Oklahoma, which has the fourth highest age-adjusted cancer death rate (177.3 per 100,000) among all states (CDC). Efforts to advance this mission are guided by a five-year Strategic Plan (2018-22) and supported by significant institutional commitments on the part of the University and State. The SCC currently has 131 members (71 Full and 60 Associate), representing 32 different academic departments at the OU Health Sciences Center (OUHSC) and OU Norman campuses. These cancer center members published 295 cancer-focused publications in peer reviewed journals. Of these, 22% involved Intra-Programmatic and 9% Inter-Programmatic collaborations. Notably, both of these percentages dipped significantly in 2020, perhaps reflective of obstacles to collaborating in the era of COVID-19. SCC member publications continued to reflect significant collaboration with scientists at other institutions (80%) and, within that category, at other NCI-Designated Cancer Centers (50%). Research at the SCC continues to reflect a strong focus on cancer problems prevalent in Oklahoma, the SCC's catchment area, and especially the state's large American Indian and rural populations that experience significantly higher cancer incidence and mortality rates. The SCC continues to be a national leader in clinical research. During the reporting period, the SCC had 666 accruals to interventional treatment trials and 634 accruals to interventional non- treatment trials. The SCC continues to be the top accruing site in the NCI's National Clinical Trials Network (NCTN), enrolling 288 patients to National Group trials in CY2020. During the reporting period, the SCC was a lead partner in an awarded consortium application (UM1CA186689) for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN), thereby achieving a primary goal in the SCC's 2018-22 Strategic Plan. Activities in the SCC's Education, Training and Career Enhancement (ETCE) Core have grown significantly, highlighted by a continued increase in peer-reviewed training funding (see above). The SCC's Community Outreach and Engagement (COE) Core is continuing to add capacity and take a lead role in promoting and coordinating research focused on the SCC catchment area. The SCC continues to be a premier site nationally for conducting community-based research with tribal partners to address the high cancer incidence and mortality rates among American Indians in the state.